Compare · UNH vs YDES
UNH vs YDES
Side-by-side comparison of UnitedHealth Group Incorporated (UNH) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both UNH and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- UNH is the larger of the two at $355.98B, about 1073.9x YDES ($331.5M).
- Over the past year, UNH is up 32.0% and YDES is down 63.2% - UNH leads by 95.2 points.
- UNH has been more active in the news (7 items in the past 4 weeks vs 5 for YDES).
- UNH has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- UnitedHealth Group Incorporated
- YD Bio Limited
- Price
- $396.55-0.58%
- $4.91+4.91%
- Market cap
- $355.98B
- $331.5M
- 1M return
- -5.03%
- +117.74%
- 1Y return
- +31.97%
- -63.25%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 5
- Recent ratings
- 25
- 0
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Latest UNH
- Chief Executive Officer, Optum Conway Patrick Hugh sold $455,910 worth of shares (1,169 units at $390.00), decreasing direct ownership by 7% to 15,328 units (SEC Form 4)
- UnitedHealthcare Expands Access to Child and Family Behavioral Coaching to 13 Million Commercial Members
- Chief Accounting Officer Stankiewicz Dennis Andrew covered exercise/tax liability with 233 shares, decreasing direct ownership by 2% to 10,058 units (SEC Form 4)
- UnitedHealth Group Board Authorizes Payment of Quarterly Dividend
- SEC Form 10-Q filed by UnitedHealth Group Incorporated
- Chief Executive Officer, Optum Conway Patrick Hugh sold $205,000 worth of shares (500 units at $410.00), decreasing direct ownership by 3% to 16,497 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by UnitedHealth Group Incorporated
- UnitedHealth Group Partners with UT Health Sciences to Expand Health Hubs to More Communities Across Tennessee
- UnitedHealth upgraded by Robert W. Baird with a new price target
- UnitedHealth Group Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest YDES
- YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
- SEC Form 424B3 filed by YD Bio Limited
- SEC Form 6-K filed by YD Bio Limited
- YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
- YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
- YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
- YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
- YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
- Director Lu Shao-Ta converted options into 5,749 units of Ordinary Shares, increasing direct ownership by 276% to 7,830 units (SEC Form 4)
- Director Chang Kochi converted options into 5,749 units of Ordinary Shares, increasing direct ownership by 276% to 7,830 units (SEC Form 4)